Abstract Session
Myopathic rheumatic diseases (polymyositis, dermatomyositis, inclusion body myositis)
Michael Bubb, MD
University of Florida
Gainesville, FL, United States
No financial relationships with ineligible companies to disclose
Taken together, the overall human experience with the intravenous infusion of ULSC has demonstrated an absence of adverse outcomes attributable to this investigational product, and in the context of DM/PM, has demonstrated early evidence of clinical improvement in multiple participants using complementary outcome measures, in the context of progressive reduction in steroid dosing.
Table 1.
Figure 1. Average total improvement score (TIS) over all timepoints for each subject - the missing subject is for a participant who signed the consent but had no study interventions.
Figure 2. MMT8 results over duration of study.
M. Bubb`: AbbVie/Abbott, 5, Alexion, 5, Amgen, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 5, GlaxoSmithKlein(GSK), 5, Restem, LLC, 5, UCB, 5; E. Handberg: Restem, LLC, 5; R. Gonzalez: Restem, LLC, 3, 4; B. Betancourt: None; J. Bostick: None; S. Long: None; K. March: Restem, LLC, 2, 5; C. Pepine: Restem, LLC, 5.